Step 1: Mechanism of Action.
Both Ropivacaine and Bupivacaine are amide local anaesthetics that work by inhibiting sodium ion influx through voltage-gated sodium channels, thereby preventing nerve depolarization and conduction. This results in reversible anaesthesia in the area of administration.
Step 2: Potency and Duration of Action.
- Bupivacaine: It is more potent than Ropivacaine, providing longer-lasting anaesthesia. Its duration of action makes it ideal for longer surgical procedures.
- Ropivacaine: Less potent than Bupivacaine, leading to shorter duration of anaesthesia. It is often used when a shorter anaesthetic effect is needed, such as in labour analgesia.
Step 3: Cardiovascular and Toxicity Profile.
- Bupivacaine: Known for its higher cardiotoxicity, especially at higher doses. It can cause arrhythmias, hypotension, and cardiac arrest in the event of accidental intravascular injection.
- Ropivacaine: Has a safer cardiovascular profile compared to Bupivacaine, with lower cardiotoxicity. It is preferred in high-risk patients due to its reduced risk of causing life-threatening cardiac arrhythmias.
Step 4: Motor Block and Sensory Block.
- Bupivacaine: More likely to cause motor block, which is desirable for certain surgical procedures where motor relaxation is needed.
- Ropivacaine: Less likely to cause motor block and is often preferred when sensory block with minimal motor impairment is required, such as during epidural anaesthesia in labour.
Step 5: Conclusion.
Ropivacaine and Bupivacaine both have their specific indications based on their pharmacological properties. Bupivacaine is more potent and longer-lasting but carries a higher risk of cardiotoxicity, while Ropivacaine offers a safer alternative, especially in high-risk patients or when less motor blockade is desired.
Match List-I with List-II:
\[
\begin{array}{|l|l|}
\hline
\textbf{List-I (Name of Drug)} & \textbf{List-II (Indication)} \\
\hline
A. \ \text{Baclofen} & I. \ \text{Spasticity} \\
B. \ \text{Diclofenac} & II. \ \text{Inflammatory pain} \\
C. \ \text{Gabapentin} & III. \ \text{Central or peripheral neurogenic pain} \\
D. \ \text{Amitryptiline} & IV. \ \text{Depression} \\
\hline
\end{array}
\]
Match List-I with List-II
\[
\begin{array}{|l|l|}
\hline
\textbf{LIST I} & \textbf{LIST II} \\
\hline
A. \ \text{Dopamine} & I. \ \text{Intradermal} \\
B. \ \text{Nitroglycerine} & II. \ \text{Intravenous} \\
C. \ \text{BCG vaccine} & III. \ \text{Subcutaneous} \\
D. \ \text{Insulin} & IV. \ \text{Sublingual} \\
\hline
\end{array}
\]
Match List-I with List-II
\[
\begin{array}{|l|l|}
\hline
\textbf{LIST-I (Pharmacological Terms)} & \textbf{LIST-II (Definitions)} \\
\hline
A. \ \text{Pharmacokinetics} & I. \ \text{It deals with the biological and therapeutic effect of the drugs including the mechanism of drug action} \\
B. \ \text{Pharmacogenetics} & II. \ \text{It deals with the absorption, distribution, metabolism and excretion of drugs} \\
C. \ \text{Pharmacodynamics} & III. \ \text{It is related with development of new dosage forms and new drug delivery system with a view to produce desired pharmacokinetics and pharmacodynamic characteristics of drug} \\
D. \ \text{Biopharmaceutics} & IV. \ \text{It deals with the study of variation in drug response and metabolism due to inherited abnormalities} \\
\hline
\end{array}
\]